[1] TORRE LA,BRAY F,SIEGEL RL,et al. Global cancer statistics,2012[J]. CA Cancer J Clin,2015,65(2):87-108.
|
[2] BRAY F,FERLAY J,SOERJOMATARAM I,et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2018,68(6):394-424.
|
[3] THOMAS MB,JAFFE D,CHOTI MM,et al. Hepatocellular carcinoma:Consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting[J]. J Clin Oncol,2010,28(25):3994-4005.
|
[4] JANG HH. Regulation of protein degradation by proteasomes in cancer[J]. J Cancer Prev,2018,23(4):153-161.
|
[5] CHENG YC,TSAI WC,SUNG YC,et al. Interference with PSMB4expression exerts an anti-tumor effect by decreasing the invasion and proliferation of human glioblastoma cells[J]. Cell Physiol Biochem,2018,45(2):819-831.
|
[6] DANTUMA NP,BOTT LC. The ubiquitin-proteasome system in neurodegenerative diseases:Precipitating factor,yet part of the solution[J]. Front Mol Neurosci,2014,7:70.
|
[7] MEARINI G,SCHLOSSAREK S,WILLIS MS,et al. The ubiquitin-proteasome system in cardiac dysfunction[J]. Biochim Biophys Acta,2008,1782(12):749-763.
|
[8] CSIZMAR CM,KIM DH,SACHS Z. The role of the proteasome in AML[J]. Blood Cancer J,2016,6(12):e503.
|
[9] WANG CY,LI CY,HSU HP,et al. PSMB5 plays a dual role in cancer development and immunosuppression[J]. Am J Cancer Res,2017,7(11):2103-2120.
|
[10] TAN S,LI H,ZHANG W,et al. NUDT21 negatively regulates PSMB2 and CXXC5 by alternative polyadenylation and contributes to hepatocellular carcinoma suppression[J]. Oncogene,2018,37(35):4887-4900.
|
[11] AUGELLO G,MODICA M,AZZOLINA A,et al. Preclinical evaluation of antitumor activity of the proteasome inhibitor MLN2238(ixazomib)in hepatocellular carcinoma cells[J].Cell Death Dis,2018,9(2):28.
|
[12] VANDEWYNCKEL YP,COUCKE C,LAUKENS D,et al. Next-generation proteasome inhibitor oprozomib synergizes with modulators of the unfolded protein response to suppress hepatocellular carcinoma[J]. Oncotarget,2016,7(23):34988-35000.
|
[13] LEE KM,LEE J,PARK CS. Cereblon inhibits proteasome activity by binding to the 20S core proteasome subunit beta type4[J]. Biochem Biophys Res Commun,2012,427(3):618-622.
|
[14] WANG H,HE Z,XIA L,et al. PSMB4 overexpression enhances the cell growth and viability of breast cancer cells leading to a poor prognosis[J]. Oncol Rep,2018,40(4):2343-2352.
|
[15] BU R,HUSSAIN AR,AL-OBAISI KA,et al. Bortezomib inhibits proteasomal degradation of IκBαand induces mitochondrial dependent apoptosis in activated B-cell diffuse large B-cell lymphoma[J]. Leuk Lymphoma,2014,55(2):415-424.
|
[16] ZHENG P,GUO H,LI G,et al. PSMB4 promotes multiple myeloma cell growth by activating NF-κB-miR-21 signaling[J]. Biochem Biophys Res Commun,2015,458(2):328-333.
|
[17] LIU R,LU S,DENG Y,et al. PSMB4 expression associates with epithelial ovarian cancer growth and poor prognosis[J].Arch Gynecol Obstet,2016,293(6):1297-1307.
|